Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Total Current Assets : $7.01 Mil (As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Parnell Pharmaceuticals Holdings's total current assets for the quarter that ended in Dec. 2018 was $7.01 Mil.

Parnell Pharmaceuticals Holdings Total Current Assets Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Total Current Assets Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

Total Current Assets

Get a 7-Day Free Trial

24.66

12.24

11.83

5.64

7.01

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
Total Current Assets	Get a 7-Day Free Trial			24.66	12.24	11.83	5.64	7.01

Parnell Pharmaceuticals Holdings Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Parnell Pharmaceuticals Holdings's Total Current Assets for the fiscal year that ended in Dec. 2018 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3.155	+	1.247	+	2.29	+	0.318
	=	7.01

Parnell Pharmaceuticals Holdings's Total Current Assets for the quarter that ended in Dec. 2018 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3.155	+	1.247	+	2.29	+	0.318
	=	7.01

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Parnell Pharmaceuticals Holdings's Liquidation Value for the quarter that ended in Dec. 2018 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.155	-	37.285	+	0.75 * 1.203	+	0.5 * 2.29
=	-32.08

Parnell Pharmaceuticals Holdings Total Current Assets Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.